A Matheson team, led by Co-Head of Corporate, David Fitzgibbon, and New York-based M&A partner David Jones, Corporate M&A partner Susan Carroll Chrysostomou and senior associate Thomas Burke, associates Leo Collins and Megan Gantly, alongside partner Brendan Colgan and senior associate Kathryn Rice (Litigation) and Cork-based senior associate Sherilyn Deane (Finance), is very pleased to have advised Horizon Therapeutics plc (“Horizon”) on the completion of its acquisition by Amgen Inc. (“Amgen”).
The acquisition, one the biggest of 2023, has been structured as an all-cash offer with a transaction value of approximately $27.5 billion and was implemented via an Irish law scheme of arrangement.
With its focus on the research, development and commercialisation of medicines for rare, autoimmune and severe inflammatory diseases, Horizon’s acquisition by Amgen Inc. will further accelerate the impact of Horizon’s medicines globally and reinforce the continued long-term growth of the firm.
